CV6 Therapeutics

Executive Summary

CV6 Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecules targeting uracil-DNA metabolism, a novel approach to enhance the efficacy of standard-of-care therapies in oncology and inflammatory diseases. Headquartered in Belfast, Northern Ireland, the company's lead oncology asset, CV6-168, is currently in Phase 1a dose-escalation trials, with initial safety and pharmacokinetic data expected in the near term. Its inflammation program, CV6-1271, is advancing toward clinical readiness. CV6's differentiated mechanism has the potential to address resistance and improve outcomes in multiple cancer types, as well as chronic inflammatory conditions. However, as an early-stage private company with no disclosed funding history or partnerships, CV6 faces typical development risks including clinical trial execution, regulatory hurdles, and capital requirements. The company's progress will be closely tied to successful demonstration of safety and early efficacy signals in ongoing trials.

Upcoming Catalysts (preview)

• Q4 2026Phase 1a data readout for CV6-168 in oncology50% success
• Q2 2027IND/CTA submission for CV6-1271 in inflammatory disease60% success
• H2 2027Potential partnership or licensing deal for CV6-16830% success